tPA (tissue plasminogen activator) is a clot-dissolving medication used in medical emergencies like strokes, heart attacks, and blood clots in the lungs. It works by activating your body’s own clot-breakdown system, restoring blood flow to tissues that are being starved of oxygen. In stroke treatment, it must be given within 4.5 hours of symptom onset, and roughly half of treated patients regain functional independence within three months.
How tPA Dissolves Blood Clots
Your body already has a built-in system for breaking down clots. A protein called plasminogen circulates in your blood at all times, but it stays inactive until something triggers it. tPA is the trigger. It latches onto the surface of a blood clot and pulls plasminogen in close, then snips it at a specific point to convert it into plasmin, an enzyme that chews through the fibrin mesh holding the clot together.
What makes tPA useful as a drug is that it preferentially works at the clot site. It binds to fibrin (the structural material of clots), which concentrates its activity right where it’s needed rather than activating clot breakdown throughout the entire bloodstream. The pharmaceutical version, called alteplase, is manufactured using recombinant DNA technology to mimic the tPA your body naturally produces, just in much higher concentrations delivered all at once.
Conditions tPA Is Used For
tPA is FDA-approved for four situations:
- Acute ischemic stroke: the most well-known use, where a clot blocks blood flow to part of the brain
- Pulmonary embolism: a blood clot lodged in the lungs
- Acute heart attack: when a clot blocks a coronary artery
- Blocked catheters: clearing clots from IV lines or dialysis catheters
It’s also used off-label for clots in the deep veins of the legs and blocked arteries in the limbs, typically delivered through a catheter threaded directly to the clot rather than through a standard IV.
The 4.5-Hour Window for Stroke
Stroke treatment with tPA is famously time-sensitive. The 2026 American Heart Association guidelines recommend treatment within 4.5 hours of symptom onset, or the last time the patient was known to be well. Every minute matters: brain tissue is dying while blood flow is blocked, and the drug becomes less effective and riskier the longer you wait.
Doctors are instructed to start treatment as quickly as possible and to avoid delays from additional imaging beyond what’s needed to rule out bleeding in the brain. The phrase “time is brain” exists for a reason. A CT scan is done first to confirm the stroke isn’t caused by bleeding (a hemorrhagic stroke), because giving a clot-dissolving drug to someone who is already bleeding would be catastrophic.
How Well It Works
In a large analysis of over 9,400 stroke patients treated with tPA, 51.7% achieved a favorable functional outcome at three months, meaning they could carry out daily activities with at most minor limitations. That’s a meaningful result considering that without treatment, ischemic strokes frequently lead to severe disability or death.
The original clinical trials that led to tPA’s approval found that 39% of treated patients achieved excellent outcomes (essentially no disability). The higher numbers in more recent data likely reflect improvements in how quickly hospitals identify and treat strokes, better patient selection, and advances in supportive care. Still, tPA is not a guarantee. Nearly half of treated patients are left with significant disability, and the drug works best when the clot is in a smaller blood vessel. Large clots blocking major arteries often require additional mechanical removal with a catheter-based procedure.
Risks and Side Effects
The most serious risk of tPA is bleeding in the brain. Because the drug dissolves clots, it can also dissolve clots that are keeping damaged blood vessels sealed. In the landmark NINDS trial, symptomatic brain hemorrhage occurred in 6% of patients who received tPA, compared to 0% in the placebo group. Other major trials have reported rates between 2.4% and 7.7%, depending on how hemorrhage was defined and measured.
This risk is why doctors screen patients carefully before giving the drug. Brain hemorrhage from tPA can be fatal or cause additional brain damage on top of the original stroke. The medical calculation is straightforward: the benefit of dissolving the clot and restoring blood flow outweighs the bleeding risk for most eligible patients within the treatment window, but not for everyone.
Who Cannot Receive tPA
Several conditions make tPA too dangerous to use. Active bleeding anywhere in the body is an obvious disqualifier. A brain scan showing any type of hemorrhage rules it out immediately, as does a history of previous brain bleeding. Blood pressure above 185/110 that can’t be brought under control also disqualifies a patient, because high pressure increases the chance that a weakened blood vessel will rupture once the clot-dissolving process begins.
Other factors that prevent treatment include significant head trauma or a stroke within the previous three months, low platelet counts, use of blood-thinning medications beyond certain thresholds, and brain tumors or abnormal blood vessel formations. If a CT scan shows that more than one-third of a brain hemisphere already shows signs of damage, the drug is withheld because the tissue is likely beyond saving and the bleeding risk outweighs any potential benefit.
Newer Alternatives
A newer version of the drug called tenecteplase is increasingly used alongside or instead of traditional tPA. Its main practical advantage is simplicity: tenecteplase is given as a single injection rather than the hour-long infusion that alteplase requires. This makes it faster to administer, especially in emergency rooms or when patients need to be transferred to another hospital for additional procedures.
A large clinical trial (ATTEST-2) comparing the two drugs in stroke patients found that tenecteplase was just as effective as alteplase for functional outcomes at 90 days, though it did not prove to be superior. The 2026 AHA stroke guidelines now endorse either drug within the 4.5-hour window. The shift toward tenecteplase in many hospitals is driven more by logistical convenience than by better outcomes, since a single bolus injection is easier to manage in a chaotic emergency setting than a prolonged infusion.